Market Movers: Celcuity (CELC) Gains 6.87% to Close at $9.49 June 23

Equities Staff  |

Celcuity Inc (NASDAQ:CELC) stock was among today's market movers, ending trading up 6.87% to $9.49 on June 23.

86,419 shares traded hands while the 30-day daily average of 73,434 shares.

The company's stock has moved 32.68% so far in 2022.

Celcuity shares have traded in a range between $4.81 and $33.01 over the past twelve months.

The company is set to release earnings on 2022-08-08.

For technical charts, analysis, and more on Celcuity visit the company profile.

About Celcuity Inc

Celcuity is a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering companion diagnostics and expanded therapeutic options for cancer patients. Celcuity's 3rd generation diagnostic platform, CELsignia, analyzes living tumor cells to untangle the complexity of the cellular activity driving a patient's cancer. This allows Celcuity to discover new cancer sub-types molecular diagnostics cannot detect. Celcuity is driven to improve outcomes for patients and to transform how pharmaceutical companies define the patient populations for their targeted therapies. Celcuity is headquartered in Minneapolis, MN.

To get more information on Celcuity Inc and to follow the company's latest updates, you can visit the company's profile page here: Celcuity Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content